The latest Ebola drugs are making people healthier, but are also raising new questions about their safety and efficacy, according to a new report by the New York Times.
The article, entitled The New Ebola Drugs Are Making the World Healthy, is based on an analysis of data from the U.S. Centers for Disease Control and Prevention.
The study found that people are taking the drugs less frequently, but the drug makers are trying to increase the number of people who are using them.
The CDC has already been working on a new drug called ZMapp, and the drugmaker Mylan has announced a new version of the Ebola vaccine called Zmapp 2.0.
The new research by the Times sheds new light on how the drugs are working.
The Times analysis suggests that ZMAPP is doing better than some of the other drug companies are predicting, and Mylan is taking more chances.
The drugmaker said it has made a small number of small improvements in ZMAP’s safety and effectiveness.
The most important change was the inclusion of the “pre-exposure prophylaxis” of the drug, which is the only step the drug manufacturer requires before giving people a shot.
This is when you take a shot that is injected into the arm.
The FDA has approved the drug to be used for a number of reasons, including for people with preexisting health conditions.
In this case, the FDA said the drug is a good option for people who already have preexisted conditions and who do not want to be exposed to Ebola.
But the drug maker said that its goal is to get as many people who have preexsisting conditions as possible on the drug.
“Our intent is to treat as many as possible who are at increased risk for severe, life-threatening exposure to the virus,” Mylan’s president, Heather Bresch, said in a statement.
The company said that about 2.5 million doses of ZMADD are now in clinical trials.
The drugs are also being tested for other conditions, such as severe malaria.
While the drugmakers say they are making a number to test the drug on, there are questions about how well the drugs will work in a real-world setting.
The U.K. has been the world’s biggest market for ZMIND and has been hit hard by the virus.
Last week, the U,K.
government announced that it had approved its first batch of ZmADD to treat severe malaria and other malaria-related conditions.
The approval comes just days after the U.,K.
began its own trial of the new drug.
Some of the data in the Times article is based off data from Mylan and Myriad Genetics, a biotechnology company, which both have large pharmaceutical companies.
The companies did not respond to requests for comment.
But in addition to ZMAMP, Myriad and Mylans data suggest that the drug should be tested for the Ebola virus more frequently.
The Centers for Medicare and Medicaid Services, the government agency that oversees the drug development and production, has been testing ZMOMP on patients for a year to see if it is effective in treating the virus, according a report from the Times.
But since the drug was approved for use against Ebola, that testing has not been active.
“If you’re going to do it in the United States, I think it’s not worth it,” Dr. Joseph Cone, a senior scientist at the National Institute of Allergy and Infectious Diseases, told the Times, adding that the data was just “too limited to say much.”
It was not clear how much testing is happening.
But a spokesman for Mylan told the New Yorker that testing is ongoing and that the company is working with regulators to ensure the drug will be safe and effective.
Mylan did not immediately respond to a request for comment from Healthline.